Compare THRY & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | RCEL |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.8M | 171.5M |
| IPO Year | 2020 | N/A |
| Metric | THRY | RCEL |
|---|---|---|
| Price | $3.83 | $4.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $9.33 | $7.88 |
| AVG Volume (30 Days) | ★ 742.1K | 209.1K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $49.82 |
| P/E Ratio | $36.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $3.22 |
| 52 Week High | $15.49 | $9.85 |
| Indicator | THRY | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 49.09 |
| Support Level | $3.46 | $4.37 |
| Resistance Level | $4.05 | $4.57 |
| Average True Range (ATR) | 0.29 | 0.37 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 66.74 | 19.25 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.